SCHEMBL4251552

SCHEMBL4251552

CCCCOC(=O)/C=C(/Oc1ccccc1[N+](=O)[O-])C(=O)OCCCC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.46
KMT2A Q03164 4/20 0.46
L3MBTL1 Q9Y468 2/20 0.44
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
POLB P06746 2/20 0.42
NPC1 O15118 2/20 0.42
RECQL P46063 1/20 0.42
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 4/20 0.41
HTT P42858 1/20 0.41
CYP1A2 P05177 1/20 0.40
MAPT P10636 1/20 0.40
CYP2C9 P11712 1/20 0.40
TDP1 Q9NUW8 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
LMNA P02545 1/20 0.40
AKR1C3 P42330 1/20 0.39
AKR1C2 P52895 1/20 0.39
AKR1C1 Q04828 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4254610 1.00 RAB9A (0.46) RAB9AKMT2AL3MBTL1GAAHPGD
SCHEMBL4251557 1.00 RAB9A (0.46) RAB9AKMT2AL3MBTL1GAAHPGD
SCHEMBL4249042 0.96 L3MBTL1 (0.47) RAB9AKMT2AL3MBTL1GAAHPGD
SCHEMBL4249037 0.96 L3MBTL1 (0.47) RAB9AKMT2AL3MBTL1GAAHPGD
SCHEMBL4252634 0.96 L3MBTL1 (0.47) RAB9AKMT2AL3MBTL1GAAHPGD
SCHEMBL4252616 0.93 RAB9A (0.47) RAB9AKMT2AL3MBTL1GAAHPGD
SCHEMBL4249056 0.93 RAB9A (0.47) RAB9AKMT2AL3MBTL1GAAHPGD
SCHEMBL4249053 0.93 RAB9A (0.47) RAB9AKMT2AL3MBTL1GAAHPGD
SCHEMBL4247741 0.86 RAB9A (0.58) RAB9AKMT2AL3MBTL1POLBNPC1
SCHEMBL4247745 0.86 RAB9A (0.58) RAB9AKMT2AL3MBTL1POLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2105432-A1 Process for Producing Chromone Compound Sumitomo Chemical Company, Limited (JP) 2009-09-30 EP disclosed
EP-2105431-A1 Process for Producing Chromone Compound Sumitomo Chemical Company, Limited (JP) 2009-09-30 EP disclosed
EP-1867626-A2 Process for producing chromone compound Sumitomo Chemical Company, Limited (JP) 2007-12-19 EP disclosed
US-20060217565-A1 Process for producing chromone compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-28 US disclosed
US-7094914-B2 Process for producing chromone compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-08-22 US disclosed
US-20050085664-A1 Process for producing chromone compound SUMITOMO CHEMICAL COMPANY, LMITED (JP) 2005-04-21 US disclosed
EP-1479667-A1 PROCESS FOR PRODUCING CHROMONE COMPOUND Sumitomo Chemical Company, Limited (JP) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085664-A1 Process for producing chromone compound ENY2, CDY1; CDY1B, CDYL RAB9A 3116/4885KMT2A 1072/4885L3MBTL1 3519/4885
US-20060217565-A1 Process for producing chromone compound ENY2, CDY1; CDY1B, CDYL RAB9A 3116/4885KMT2A 1072/4885L3MBTL1 3519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.